Brilliant scientists from the University of the Philippines – Diliman College of Science (UPD-CS) have made a potentially ground-breaking discovery in the field of cancer treatment. By modifying the compound deguelin, which is commonly used in pesticides and fish poisons, researchers have developed a novel class of compounds that show promising results as anticancer agents. The modified variants of deguelin have demonstrated improved efficacy and safety, surpassing even commercially available anticancer drugs. The study, conducted by Science Research Specialists Dr. John Alfon Francisco and Dr. Monissa Paderes from UPD-CS Institute of Chemistry (UPD-CS IC), has shown particular promise in the treatment of colon, lung, and breast cancer.
Dr. Francisco and Dr. Paderes addressed the concern surrounding the compound’s original use in pesticides by altering its structure. This alteration resulted in improved characteristics and decreased negative impacts on human cancer cell cultures. The chemists at UPD-CS have successfully generated multiple variations of the compound, with some versions surpassing the effectiveness of the widely used anticancer drug doxorubicin in treating specific types of cancer.
The modified compounds offer a more straightforward and cost-effective means of production compared to those previously studied. By truncating a section of deguelin called the BCE ring, the scientists were able to create a new version of the deoxybenzoin compound known for its antibacterial and antioxidant properties. However, UPD-CS emphasizes that the research is still in its early stages despite its ground-breaking potential.
Dr. Paderes stated, The goal would be to advance these compounds toward clinical trials and potential development as novel anticancer therapeutics. If the positive results from animal trials are replicated in human clinical trials, UPD-CS plans to seek approval from the Food and Drug Administration (FDA) to deploy these compounds as effective and safe cancer treatments.
It is essential to note that the research team is committed to upholding legal and ethical standards. The scientists aim to provide a viable solution for cancer treatment while ensuring the safety and well-being of patients. With the potential of their groundbreaking discovery, the UPD-CS researchers are dedicated to improving the lives of those affected by colon, lung, and breast cancer.
As the research progresses, the scientific community eagerly awaits further developments in this innovative approach to cancer treatment. The modified compounds derived from deguelin offer a ray of hope to millions of cancer patients worldwide. Should the compounds prove successful in human clinical trials and receive FDA approval, they could potentially revolutionize the field of oncology, providing new avenues for effective treatment and improved patient outcomes. The University of the Philippines – Diliman College of Science continues to lead the way in scientific innovation, demonstrating that groundbreaking discoveries can emerge from unexpected sources.
